Rockwell Med Inc Stock Price, News & Analysis

Rockwell Medical, a biopharmaceutical company, will host a conference call on November 9, 2020, at 4:30 p.m. ET, to discuss its financial results for Q3 2020 and recent operational developments. Interested participants can join by dialing (877) 383-7438 for local access or (678) 894-3975 for international access, with a conference ID of 7679074. The call will also be available via live webcast. Rockwell Medical specializes in iron deficiency treatments for patients with end-stage kidney disease through its FDA-approved products, Triferic Dialysate and Triferic AVNU.

Rockwell Medical (Nasdaq: RMTI) announced that two abstracts have been accepted for poster presentations at the ASN Virtual Kidney Week 2020 from October 20 to 25. The abstracts focus on the use of Triferic in hemodialysis patients, highlighting its role in maintaining hemoglobin levels and reducing the need for IV iron. Triferic is FDA-approved and aims to transform iron deficiency treatment in end-stage kidney disease patients.

Rockwell Medical (RMTI) announced new indications for its ferric pyrophosphate citrate (FPC) platform during a recent conference call. The company is pursuing development for treating iron deficiency anemia (IDA) in home infusion patients and assessing FPC's potential for acute heart failure. A Type C meeting with the FDA is anticipated in Q1 2021 for home infusion and in H2 2021 for acute heart failure. Rockwell Medical remains well-capitalized to fund both its dialysis business and clinical advancements, with market opportunities for IDA treatment estimated at $600 million annually.

Rockwell Medical (RMTI) announced a registered direct offering of 23,178,809 common stock shares and accompanying short-term warrants, priced at $1.51 per share. This transaction is expected to yield approximately $35 million in gross proceeds. The funds will be directed towards advancing the development of ferric pyrophosphate citrate for anemia treatment, particularly in home infusion, alongside general corporate purposes. The offering is projected to close around September 25, 2020, subject to customary conditions.

Rockwell Medical (RMTI) announced the appointment of Russell L. Skibsted as Executive Vice President, Chief Financial Officer, and Chief Business Officer effective September 15, 2020. Skibsted's extensive experience in the life sciences sector, including previous roles at AgeX and BioTime, aligns with the company's focus on enhancing its commercial strategy for Triferic and Triferic AVNU in kidney dialysis. He aims to drive business development and financial operations, ultimately increasing shareholder value.

Rockwell Medical (Nasdaq: RMTI) has announced an exclusive license agreement with Jeil Pharmaceutical Co., Ltd. for the commercialization of Triferic in South Korea. Under this agreement, Jeil will develop and market Triferic, with Rockwell supplying the product. The deal includes an upfront fee, milestone payments, and royalties on sales. Triferic aims to address iron deficiency in over 78,000 hemodialysis patients in South Korea. Sales are expected to commence in early 2022, pending regulatory approval.

Rockwell Medical (Nasdaq: RMTI) will host a conference call and webcast on September 24, 2020, at 4:30 p.m. ET, to discuss novel applications of ferric pyrophosphate citrate (FPC) for treating iron deficiency in home infusion therapy and acute heart failure patients. Key opinion leaders will join the call alongside company representatives. The goal is to explore new indications for FPC technology beyond hemodialysis. Access details are provided for interested stakeholders.

Rockwell Medical announced that its executive management team will present at two important investor conferences in September 2020. The first is the H.C. Wainwright 22nd Annual Global Investment Conference on September 14 at 4:00 PM EDT, followed by the Cantor Fitzgerald Virtual Global Healthcare Conference on September 15 at 10:40 AM EDT. Both presentations will be available via live webcast on the company's website for 30 days.

Rockwell Medical focuses on transforming anemia management, particularly for end-stage kidney disease patients, with FDA-approved therapies like Triferic Dialysate and Triferic AVNU.

Rockwell Medical has appointed Dr. Allen R. Nissenson to its Board of Directors effective June 11, 2020. An expert in kidney disease and former Chief Medical Officer of DaVita Kidney Care, Dr. Nissenson's extensive experience is expected to bolster the company's mission of enhancing anemia management in end-stage renal disease (ESRD) patients. This strategic move aims to strengthen Rockwell's leadership as it seeks to expand the reach of its FDA-approved products, Triferic Dialysate and Triferic AVNU, both crucial for iron replacement in hemodialysis patients.